List view / Grid view
16 December 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announces that the first patient has been enrolled in the RE-SPECT ESUS™ phase III study to investigate the efficacy and safety of dabigatran etexilate for the prevention of recurrent Embolic Stroke of Undetermined Source, also called ESUS...
9 December 2014 | By Boehringer Ingelheim
New data demonstrate that a five-minute infusion of the investigational specific antidote idarucizumab led to immediate, complete and sustained reversal of the anticoagulant effect of Pradaxa® (dabigatran etexilate)...
8 December 2014 | By Boehringer Ingelheim
The unveiling of the new technology centre in Biberach represents the temporary completion of a remodelling and construction phase in chemical development at Boehringer Ingelheim’s largest research and development location...
27 November 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the European Commission has granted EU marketing authorisation for Vargatef® (nintedanib*), valid for the 28 countries within the EU...
21 November 2014 | By Boehringer Ingelheim
Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for nintedanib (suggested brand name OFEV®) for the treatment of patients with idiopathic pulmonary fibrosis (IPF).
19 November 2014 | By Boehringer Ingelheim
Two new real-world data analyses presented at the American Heart Association’s Scientific Sessions 2014 independently demonstrate that routine treatment with Pradaxa® (dabigatran etexilate) was associated with fewer major bleeds and strokes compared to warfarin...
19 November 2014 | By Boehringer Ingelheim
New data on the investigational antidote idarucizumab show that it can reverse the effect of the oral anticoagulant Pradaxa® (dabigatran etexilate) on both blood coagulation and the blood clotting mechanism...
28 October 2014 | By Boehringer Ingelheim
Global top 20 pharma company streamlines R&D IT with cross-domain platform...
21 October 2014 | By Boehringer Ingelheim
Boehringer Ingelheim today announced the enrolment of the first patient in a new global Phase III study in patients with advanced colorectal cancer...
1 October 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that adult asthma patients could benefit from a new treatment...
29 September 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for the approval of nintedanib*...
16 September 2014 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company presented results from a 52-week Phase III study that demonstrated sustained efficacy of the investigational empagliflozin/linagliptin combination tablet in adults with Type 2 Diabetes...
15 September 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the multinational RE-VERSE AD clinical trial – the study investigating the emergency reversal of the anticoagulant effect of dabigatran – has been initiated in the UK...
10 September 2014 | By Boehringer Ingelheim
The European Commission granted marketing authorisation for Eli Lilly and Company and Boehringer Ingelheim’s insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged 2 years and above...
8 September 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the indication for Spiriva® (tiotropium) Respimat®* in asthma has been accepted by the regulatory authorities in the EU...
